Our team is dedicated to improve care fast. We do this by developing applications for medical treatments and diagnostics that are closely aligned with current practices. These developments as well as our own innovations spawn limitless opportunities to refine and improve care.

It is our main goal to introduce groundbreaking therapeutic radioligands, providing alternative cancer treatment options


Our team is moving fast: A full clinical development plan for our first base technology (the NC-Scan) including location selection, is available. Registration as a diagnostic tool with the FDA and the EMA is expected within 40 months of financing.

We are currently working on several products in the development program for the treatment of tumors with naturally occurring necrosis as well as on internal irradiation with necrosis caused by treatments with chemotherapy that work partially but that do not kill enough tumorcells

The first applications for therapeutics are Therm-Core and Actiono-Core. Both applications work by the same concept; by labeling a radioligand probe, cancercells can be destroyed from within.

Our radioligand diagnostic tool, NC-Scan visualizes all types of necrosis in living tissue within 24-36 hours of administration, including cancer therapy-induced necrosis (destroyed cancer cells). Thanks to this technique cancer-patients will know within 24-36 hours if their chemotherapy is effective. The FDA and EMA registration of the NC-Scan is an important step for the speed of the development and registration of our therapeutic radioligand.

The Coretag technology is based on the detection of necrosis to be used for visualization and as a carrier for therapeutic purposes. Necrosis is non-programmed cell death. A healthy human body does not contain necrotic tissue. It is induced by external factors or diseases, such as radiation, burns, myocardial infarction, trauma and loss of blood supply. Necrosis also appears as a result of cancer treatments such as immunotherapy, chemotherapy and radiotherapy. 

Coretag is the first biotech company who introduces the necrosis targeting probe. This probe binds to the proteins tubulin and actin, which form the intracellular cytoskeleton of any cell.

Necrosis should not be confused with apoptosis, the programmed on-going process of cell renewal in any healthy human body. In apoptosis, cells are dying according to plan and are removed by macrophages in a well-managed process, the cell membrane stays intact, doesn’t lose its integrity and the proteins do not become available as a target for the Necrosis Probe.

Coretag is working on solutions to improve cancer care and refine treatments for better results and less complications. This is important for the patient, but it also causes a significant decrease in cancer care costs. And that is necessary: The cost of cancer-related healthcare worldwide is expected to quadruple in 2040 as a result of an exponential increase in cancer incidence.

New disease-specific and personalized medicines are promising, but also extremely expensive. Add that chemotherapy does not work for 65% of all solid tumors. Spending budgets on ineffective therapies without the desired results requires innovative solutions.

Our platform technology has the potential to not only greatly improve the quality of (cancer)treatment, but to meet a wide still unmet medical need in a wide range of medical conditions involving necrosis – such as strokes and heart attacks.

After 6 years of pre-clinical research Coretag developed the first platform technology to target necrotic tissue in living human. We are moving fast: A full clinical development plan for NC-Scan, including location selection, is available.

Coretag aims to launch NC-Scan for use in patients in 2021. Because of relative short time to market and revenues of NC-Scan Coretag focus on bringing NC-Scan to market and parallel development of therapeutic pipelines. The FDA and EMA registration of our diagnostic tool, the NC-Scan is an important step for the speed of the development and registration of our therapeutic radioligands.

Clinical Development & Trials for registration will in a short time take place in world leading cancer institutes.

Coretag has its origins in the Netherlands. In 2019 Coretag’s Head Office is based in Innovation Park Basel, Switserland. We strive to launch an international pipeline of production  development

Frequently Asked Questions

Pre-clinical studies started in 2012. The discovery of our radioligand was proved to be working in animal models and now Coretag is preparing the clinical studies. Clinical studies for patients with specific solid tumors will start in Europe in 2020 at world-renowned leading (cancer) institutes. Preparations for clinical trials of the NC-Scan are already in full swing. Coretag aims to launch the NC-Scan for use in patients in 2022.

If you would like to stay up to date on our news and progress, subscribe to our newsletter.

Our technology is administered intravenously to the patient.

If you would like to stay up to date of our news and progress, subscribe to our newsletter.

In our first clinical studies we want to prove that our NC-scan technology can indicate within 24-36 hours after administering medication whether a chemotherapy-drug works or not. After these clinical studies we will continue developing our technology for therapeutic purposes. Coretag’s platform technology is therefore intended to improve the quality of (cancer) treatments. If you, as a patient, want to know for certain whether you are still eligible for treatment and able to participate in one of our clinical studies, you should talk to your doctor.